cardiolytix.com

What It Is

Cardiolytix is a medical AI company founded in Boston in 2019. Its core product, CardioScan AI, is designed for hospitals and health systems, using AI to analyze standard 12-lead ECGs. The platform can process an ECG within 30 seconds, identify arrhythmias, ischemic changes, and clues related to structural heart disease, and write risk scores and analysis results back to the EHR for clinical triage and decision support.

Core Capabilities and Integrations

The product covers four main capability areas: detection of arrhythmias such as atrial fibrillation, ventricular tachycardia, supraventricular tachycardia, atrioventricular block, and bundle branch block; analysis of STEMI/NSTEMI, ST-segment, and T-wave abnormalities; morphological assessment such as left/right ventricular hypertrophy, chamber enlargement, and pathological Q waves; and continuous ECG trend monitoring plus prognostic risk scoring. The website says the model was trained on more than 2 million labeled ECGs, has already analyzed 50,000+ ECGs, and reports 89% sensitivity, but it does not provide more complete task-level metrics. Technically, it supports HL7 FHIR and can integrate with EHR systems such as Epic, Oracle Health/Cerner, MEDITECH, and Allscripts. The stated minimum deployment timeline is 6 weeks.

Pricing, Compliance, and Limitations

Pricing is not public; the site only offers a Request a Demo option, making it more suitable for enterprise procurement processes. On compliance, the platform claims HIPAA compliance, encryption of PHI in transit and at rest, audit logs, and the ability to sign a BAA; SOC 2 Type I has been completed, and it is ISO 13485:2016 certified. One important caveat is that FDA Class II 510(k) status is currently Submitted/Under Review, not cleared. The clinical evidence page discloses limited detail in its main text, so buyers should request full multi-center validation data, specificity, negative/positive predictive values, failure rates, and clear liability boundaries before procurement.

Pros, Cons, and Best Fit

Its strengths are fast analysis, coverage of multiple cardiac abnormalities, EHR workflow integration, and automated alerts. It is suitable for emergency departments, cardiology departments, regional medical groups, and health systems looking to improve ECG triage efficiency. Its drawbacks are opaque pricing, no disclosed free trial, FDA status still under review, and the fact that its output is intended for decision support only and cannot replace physician diagnosis.

China Access and Alternatives

The website does not disclose information about China access, payment, local deployment, NMPA registration, or Chinese-language support, so china_access can only be assessed as unknown. Chinese medical institutions considering similar capabilities should focus on comparing locally compliant ECG AI vendors, their existing hospital ECG management systems, and the feasibility of using international medical AI platforms in terms of network access, cross-border data transfer, payment, and regulatory approval.